NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Pfizer (NYSE:PFE) reported positive results from a Phase 3 study of its drug Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. The study, called TALAPRO-3, ...

New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Te ...

In this observational study, a higher consumption of tomatoes was associated with a significantly lower risk of prostate cancer. The same study also found a risk reduction with consumption of ...

Cases of prostate cancer are on the rise in California, according to new research. A study by UC San Francisco (UCSF) included nearly 388,000 men who had prostate cancer between 2004 and 2021.

Discover a study that concludes that the reduction in PSA screening has had a widespread impact on men in the US.